MA33818B1 - Nouveaux antagonistes du récepteur ccr2 et leurs utilisations - Google Patents

Nouveaux antagonistes du récepteur ccr2 et leurs utilisations

Info

Publication number
MA33818B1
MA33818B1 MA34961A MA34961A MA33818B1 MA 33818 B1 MA33818 B1 MA 33818B1 MA 34961 A MA34961 A MA 34961A MA 34961 A MA34961 A MA 34961A MA 33818 B1 MA33818 B1 MA 33818B1
Authority
MA
Morocco
Prior art keywords
receptor antagonists
ccr2 receptor
new
new ccr2
diseases
Prior art date
Application number
MA34961A
Other languages
Arabic (ar)
English (en)
Inventor
Kai Gerlach
Heiner Ebel
Sara Frattini
Riccardo Giovannini
Christoph Hoenke
Rocco Mazzaferro
Marco Santagostino
Stefan Scheuerer
Christofer Tautermann
Thomas Trieselmann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA33818B1 publication Critical patent/MA33818B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Cette invention concerne de nouveaux antagonistes du ccr2 (récepteur 2 des chimiokines cc) de formule (i) et leur utilisation pour fabriquer des médicaments destinés à traiter des affections et des maladies, en particulier, des maladies pulmonaires comme l'asthme et la bpco.
MA34961A 2009-12-17 2012-06-14 Nouveaux antagonistes du récepteur ccr2 et leurs utilisations MA33818B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09179555 2009-12-17
EP10162621 2010-05-12
PCT/EP2010/069549 WO2011073154A1 (fr) 2009-12-17 2010-12-13 Nouveaux antagonistes du récepteur ccr2 et leurs utilisations

Publications (1)

Publication Number Publication Date
MA33818B1 true MA33818B1 (fr) 2012-12-03

Family

ID=43533115

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34961A MA33818B1 (fr) 2009-12-17 2012-06-14 Nouveaux antagonistes du récepteur ccr2 et leurs utilisations

Country Status (36)

Country Link
US (6) US8765949B2 (fr)
EP (3) EP2513093B1 (fr)
JP (1) JP5632014B2 (fr)
KR (1) KR101530234B1 (fr)
CN (1) CN102933579B (fr)
AP (1) AP3170A (fr)
AR (1) AR079636A1 (fr)
AU (1) AU2010332969B2 (fr)
BR (1) BR112012015873B1 (fr)
CA (1) CA2782464C (fr)
CL (1) CL2012001311A1 (fr)
CO (1) CO6650336A2 (fr)
CY (1) CY1115873T1 (fr)
DK (1) DK2513093T3 (fr)
EA (1) EA024397B1 (fr)
EC (1) ECSP12012010A (fr)
ES (2) ES2674275T3 (fr)
GE (1) GEP20146124B (fr)
HR (1) HRP20141143T1 (fr)
IL (1) IL219421A (fr)
MA (1) MA33818B1 (fr)
ME (1) ME01908B (fr)
MX (2) MX346393B (fr)
MY (1) MY160471A (fr)
NZ (1) NZ599770A (fr)
PE (1) PE20121614A1 (fr)
PH (1) PH12012501215A1 (fr)
PL (2) PL2513093T3 (fr)
PT (2) PT2513093E (fr)
RS (1) RS53555B1 (fr)
SG (1) SG181722A1 (fr)
SI (1) SI2513093T1 (fr)
TN (1) TN2012000300A1 (fr)
TW (1) TWI473800B (fr)
UY (1) UY33109A (fr)
WO (1) WO2011073154A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2687931C (fr) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Antagonistes des recepteurs ccr2 et utilisations de ceux-ci
CN102256963B (zh) * 2008-12-19 2014-06-11 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
MX346393B (es) 2009-12-17 2017-03-17 Centrexion Therapeutics Corp Nuevos antagonistas del receptor ccr2 y usos de los mismo.
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
WO2011141477A1 (fr) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Nouveaux antagonistes du récepteur ccr2, leur procédé de production et leur utilisation en tant que médicaments
WO2011144501A1 (fr) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Antagonistes du récepteur ccr2 et leurs utilisations
WO2011147772A1 (fr) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Antagonistes du récepteur ccr2
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
JP5786257B2 (ja) * 2011-06-16 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の選択的ｃｃｒ２拮抗薬
WO2013010839A1 (fr) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Antagonistes de ccr2 nouveaux et sélectifs
CA2852160A1 (fr) 2011-10-28 2013-05-02 Galderma Research & Development Nouveaux marqueurs d'infiltrat leucocytaire de rosacee et utilisations de ceux-ci
US8877185B2 (en) 2012-05-10 2014-11-04 Stan S. Sastry Managing and treating keloids
WO2016081801A1 (fr) * 2014-11-21 2016-05-26 Millennium Pharmaceuticals, Inc. Utilisation d'un antagoniste anti-ccr2 dans le traitement d'une maladie infectieuse
CA2985194C (fr) 2015-05-21 2024-05-21 Chemocentryx, Inc. Modulateurs du ccr2
AU2016287584B2 (en) * 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
SG10202012080UA (en) * 2016-06-03 2021-01-28 Chemocentryx Inc Method of treating liver fibrosis
CN109562086A (zh) * 2016-06-13 2019-04-02 坎莫森特里克斯公司 治疗胰腺癌的方法
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
CN108017599B (zh) * 2016-11-04 2020-03-03 上海爱科百发生物医药技术有限公司 [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法
MX388165B (es) 2016-11-23 2025-03-19 Chemocentryx Inc Método para tratar glomeruloesclerosis segmentaria focal
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
CA3075638A1 (fr) 2017-09-25 2019-03-28 Chemocentryx, Inc. Polytherapie utilisant un antagoniste du recepteur 2 de la chimiokine (ccr2) et un inhibiteur pd-1/pd-l1
BR112020007183A2 (pt) 2017-10-11 2020-09-24 Chemocentryx, Inc. tratamento de glomeruloesclerose focal segmentado com antagonistas de ccr2
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
CN112105353B (zh) 2018-01-08 2024-04-19 凯莫森特里克斯股份有限公司 Ccr2拮抗剂治疗实体瘤的方法
US20210322412A1 (en) * 2020-04-20 2021-10-21 Centrexion Therapeutics Corporation Methods and compositions for treating a coronavirus infection
NL2026714B1 (en) * 2020-10-20 2022-06-16 Lumicks Ca Holding B V Improved detection of lymphocyte - target cell interaction

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US568885A (en) * 1896-10-06 Can-seaming mechanism
US213428A (en) * 1879-03-18 Improvement in harrow-teeth
US4032526A (en) 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
US4426382A (en) 1980-02-13 1984-01-17 Sankyo Company Limited 4-Amino-6,7-dimethoxy-2-piperazinylquinazoline derivatives, their preparation and use
DE3517617A1 (de) 1985-05-15 1986-11-20 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Neue pyridaziniumverbindungen, verfahren zu deren herstellung und diese enthaltende fungizide und algizide mittel
JPS6319745Y2 (fr) 1985-11-07 1988-06-01
JPS61165445A (ja) 1986-01-08 1986-07-26 株式会社巴組鐵工所 振動を減少しうる床構造
US5096916A (en) 1990-05-07 1992-03-17 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
CA2146019A1 (fr) 1992-10-23 1994-05-11 Howard B. Broughton Ligands de sous-types de recepteurs dopaminergiques
JP3166376B2 (ja) 1993-02-03 2001-05-14 松下電器産業株式会社 熱利用装置
US5629235A (en) 1995-07-05 1997-05-13 Winbond Electronics Corporation Method for forming damage-free buried contact
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
JP4570773B2 (ja) 1997-10-27 2010-10-27 ニューロサーチ、アクティーゼルスカブ ニコチン性アセチルコリンレセプターに於けるコリン作動性リガンドとしてのヘテロアリールジアザシクロアルカン
CA2350081A1 (fr) 1998-11-20 2000-06-02 G.D. Searle & Co. Procede de preparation de pyrazoles a substitution en position 5 a l'aide de dithietanes
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
TR200103214T2 (tr) 1999-05-04 2002-03-21 Schering Corporation CCR5 antagonistleri olarak yararlì piperazin trevleri.
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
AU5741301A (en) 2000-05-22 2001-12-03 Aventis Pharm Prod Inc Arylmethylamine derivatives for use as tryptase inhibitors
DK1326862T3 (da) 2000-10-12 2004-11-22 Boehringer Ingelheim Pharma Krystallinsk monohydrat af tiotropiumbromid, fremgangsmåde til fremstilling deraf og anvendelse deraf til fremstilling af et lægemiddel
AR035700A1 (es) 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
CA2450961C (fr) 2001-06-22 2010-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substance anticholinergique cristalline, procedes de production et son utilisation pour la production de composition pharmaceutique
US20050143372A1 (en) 2001-10-30 2005-06-30 Shomir Ghosh Compounds, pharmaceutical compositions and methods of use therefor
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
CN1628109A (zh) 2002-02-05 2005-06-15 诺沃挪第克公司 新颖的芳基－与杂芳基－哌嗪
JP2003240776A (ja) 2002-02-13 2003-08-27 Horiba Ltd クロマトグラフリーダを用いる測定方法およびそれに用いる試験片ホルダ並びにクロマトグラフリーダを用いる検査／測定装置
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
MXPA04007775A (es) 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Derivados de sulfonilo como novedosos inhibidores de la histona desacetilasa.
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
WO2003090748A1 (fr) 2002-04-24 2003-11-06 Takeda Pharmaceutical Compay Limited. Utilisation de composes a antagonisme anti-ccr
SI1501507T1 (sl) 2002-04-29 2008-12-31 Merck & Co Inc Tetrahidropiranil ciklopentil tetrahidropiridopiridin modulatorji s kemokinsko receptorsko aktivnostjo
US20040082551A1 (en) 2002-06-05 2004-04-29 Benson Alan G. Novel pyrazoles and their use as p38 kinase inhibitors
AU2003270199A1 (en) 2002-09-13 2004-04-30 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
SE0203304D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
US20040147561A1 (en) 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
WO2004074438A2 (fr) * 2003-02-14 2004-09-02 Smithkline Beecham Corporation Antagonistes de ccr8
BRPI0408284B8 (pt) 2003-03-12 2021-05-25 Kudos Pharm Ltd compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos
DE602004015269D1 (de) 2003-04-23 2008-09-04 Glaxo Group Ltd Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten.
FR2854158B1 (fr) 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
ES2291913T3 (es) 2003-07-18 2008-03-01 Glaxo Group Limited Piperidinas sustituidas como ligandos del receptor h3 de la histamina.
AU2004259263B2 (en) 2003-07-29 2010-12-16 High Point Pharmaceuticals, Llc Pyridazinyl- piperazines and their use as histamine H3 receptor ligands
CN102344398B (zh) 2003-12-18 2015-02-25 因赛特公司 作为趋化因子受体调控剂的3-环烷基氨基吡咯烷衍生物
GB0403155D0 (en) 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
JP4845873B2 (ja) 2004-03-03 2011-12-28 ケモセントリックス インコーポレーティッド 二環式および架橋した窒素複素環
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
JP2007531753A (ja) 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非イミダゾール系複素環式化合物
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
WO2006001958A2 (fr) 2004-05-21 2006-01-05 Merck & Co., Inc. Modulateurs heterocycliques et carbocycliques d'amino cyclopentyle de l'activite du recepteur de la chimiokine
MEP8409A (en) 2004-06-02 2011-12-20 Fused heterocyclic compound
FR2871157A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Produits biaryl aromatiques, compositions les contenant et utilisation
CA2570637A1 (fr) 2004-06-24 2006-02-02 Wenqing Yao Piperidines a substitution n et utilisation de ces dernieres en tant que substances pharmaceutiques
NZ552173A (en) 2004-06-25 2010-07-30 Janssen Pharmaceutica Nv Quaternary salt CCR2 antagonists
EA012649B1 (ru) * 2004-06-28 2009-12-30 Инсайт Корпорейшн 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
CN1976702A (zh) * 2004-06-28 2007-06-06 因赛特公司 作为趋化因子受体调节剂的3－氨基环戊烷甲酰胺类
MX2007002318A (es) 2004-08-26 2007-04-17 Kudos Pharm Ltd Derivados de ftalazinona substituidos con 4-heteroarilmetilo.
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
CA2580855A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
WO2006038734A1 (fr) 2004-10-08 2006-04-13 Astellas Pharma Inc. Dérivés de la pyridazinone inhibiteurs de cytokines
WO2006050389A2 (fr) 2004-11-02 2006-05-11 Northwestern University Composes pyridazine, compositions et procedes associes
UY29219A1 (es) 2004-11-22 2006-04-28 Incyte Corp Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida
DE102004061751A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Cyanoguanidin-substituierte Pyrazoline
EP2607362B1 (fr) 2005-02-17 2014-12-31 Astellas Pharma Inc. Dérivés des carboxylates de pipéridine et pipérazine comme inhibiteurs de FAAH
EP2527337A1 (fr) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibiteurs de la 11-bêta hydroxystéroïde déshydrogénase de type I
WO2006113140A2 (fr) 2005-04-15 2006-10-26 Elan Pharmaceuticals, Inc. Nouveaux composes s'utilisant dans l'antagonisme du recepteur de bradykinine b1
EP1871762A2 (fr) 2005-04-18 2008-01-02 Neurogen Corporation Antagonistes cb1 heteroaryle substitue
NZ564065A (en) 2005-05-20 2011-03-31 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
EP1909797A4 (fr) 2005-08-02 2013-02-27 Neurogen Corp Dipipérazinyl cétones et analogues apparentés
GB0517184D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
AR055203A1 (es) 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
TW200800999A (en) * 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
BRPI0616575A2 (pt) 2005-09-27 2011-06-21 Irm Llc compostos e composições contendo diarilamina, seu uso como moduladores de receptores de c-kit bem como método para sua produção
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US20100016289A1 (en) 2005-11-01 2010-01-21 Kevin Sprott Compounds Useful as Antagonists of CCR2
CA2627900A1 (fr) 2005-11-14 2007-08-16 Irm Llc Composes et compositions servant de modulateurs du lxr
EP1970373A1 (fr) * 2005-12-02 2008-09-17 Mitsubishi Tanabe Pharma Corporation Compose heterocyclique alicyclique
KR20080076962A (ko) 2005-12-20 2008-08-20 노파르티스 아게 대사성 글루타메이트 수용체 조절제로서의 니코틴산 유도체
IL172838A (en) 2005-12-27 2010-06-16 Joma Int As Methods for production of metal oxide nano particles with controlled properties and nano particles and preparations produced thereby
WO2007084868A2 (fr) 2006-01-17 2007-07-26 Kalypsys, Inc. Traitement d'une inflammation et de troubles associes par l'activation de la reponse upr (proteine depliee)
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2465850B1 (fr) 2006-02-28 2016-11-23 Dart Neuroscience (Cayman) Ltd Composés thérapeutiques
EP2024353A2 (fr) 2006-03-16 2009-02-18 Pfizer Products Inc. Pyrazoles
EP2013174B1 (fr) 2006-04-11 2013-05-08 Merck Sharp & Dohme Corp. Alcanes à substitution diaryle
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
WO2007127448A2 (fr) 2006-04-28 2007-11-08 Northwestern University Sels de composés de pyridazine
EP2044051B1 (fr) 2006-06-22 2010-01-27 BIOVITRUM AB (publ) Dérivés de pyridine et de pyrazine utilisés en tant qu'inhibiteurs de la kinase mnk
CA2657247A1 (fr) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Composes modulant le recepteur cb2
GB0617575D0 (en) 2006-09-06 2006-10-18 Syngenta Ltd Herbicidal compounds and compositions
WO2008039645A1 (fr) 2006-09-25 2008-04-03 Boehringer Ingelheim International Gmbh Composés modulant le recepteur cb2
US8754107B2 (en) 2006-11-17 2014-06-17 Abbvie Inc. Aminopyrrolidines as chemokine receptor antagonists
DK2120579T3 (da) 2006-12-28 2014-02-03 Abbvie Inc Inhibitorer af poly(ADP-ripose)polymerase
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
FR2915552B1 (fr) 2007-04-27 2009-11-06 Technip France Conduite tubulaire flexible pour le transport d'hydrocarbures gazeux.
CA2687931C (fr) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Antagonistes des recepteurs ccr2 et utilisations de ceux-ci
EP2173735B1 (fr) 2007-07-02 2012-01-11 F. Hoffmann-La Roche AG Dérivés imidazolés comme antagonistes du récepteur ccr2
US7977358B2 (en) 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
JP5303557B2 (ja) 2007-08-22 2013-10-02 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤である２−ヘテロアリールアミノ−ピリミジン誘導体
WO2009043747A2 (fr) 2007-10-01 2009-04-09 F. Hoffmann-La Roche Ag Nouveaux dérivés de biaryle
MX2010003868A (es) 2007-10-09 2010-04-27 Hoffmann La Roche Cis-imidazolinas quirales.
WO2009048238A2 (fr) 2007-10-12 2009-04-16 Jong O Whang Outil de serrage pour lacet de chaussure
WO2009067406A1 (fr) 2007-11-20 2009-05-28 Janssen Pharmaceutica N.V. Composés pyridylamide substitués comme modulateurs du récepteur h3 de l'histamine
WO2009066084A1 (fr) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2-morpholinopyrimidines et leur utilisation en tant qu'inhibiteurs de kinase pi3
JP5385297B2 (ja) 2007-11-22 2014-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
EP2062889A1 (fr) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Composés
JP5432249B2 (ja) 2008-06-18 2014-03-05 エフ．ホフマン−ラ ロシュ アーゲー 新規なヘテロアリールカルボキシアミド誘導体
AU2009279787B2 (en) 2008-08-04 2014-05-29 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
AU2009289378A1 (en) 2008-09-02 2010-03-11 Boehringer Ingelheim International Gmbh Novel benzamides, production thereof, and use thereof as medicaments
KR20110063485A (ko) 2008-09-25 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 선택적으로 조절하는 설포닐 화합물
CN102256963B (zh) * 2008-12-19 2014-06-11 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
AU2010215041A1 (en) 2009-02-23 2011-07-28 Merck Canada Inc. Heterocyclic derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
MX346393B (es) 2009-12-17 2017-03-17 Centrexion Therapeutics Corp Nuevos antagonistas del receptor ccr2 y usos de los mismo.
US20130143905A1 (en) 2009-12-17 2013-06-06 Boehringer Ingelheim International Gmbh Novel antagonists for ccr2 and uses thereof
JP5746228B2 (ja) 2010-03-05 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節するテトラゾール化合物
WO2011141477A1 (fr) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Nouveaux antagonistes du récepteur ccr2, leur procédé de production et leur utilisation en tant que médicaments
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
WO2011144501A1 (fr) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Antagonistes du récepteur ccr2 et leurs utilisations
WO2011147772A1 (fr) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Antagonistes du récepteur ccr2
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
JP5786257B2 (ja) 2011-06-16 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の選択的ｃｃｒ２拮抗薬
WO2013010839A1 (fr) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Antagonistes de ccr2 nouveaux et sélectifs
JP6229575B2 (ja) 2014-03-31 2017-11-15 京セラドキュメントソリューションズ株式会社 画像処理装置
AU2016287584B2 (en) * 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate

Also Published As

Publication number Publication date
US11046706B2 (en) 2021-06-29
EP2813503B1 (fr) 2016-04-20
WO2011073154A1 (fr) 2011-06-23
ES2524829T3 (es) 2014-12-12
KR101530234B1 (ko) 2015-06-19
EA024397B1 (ru) 2016-09-30
MX2012006964A (es) 2012-07-17
RS53555B1 (sr) 2015-02-27
AP2012006276A0 (en) 2012-06-30
TN2012000300A1 (en) 2013-12-12
KR20120123652A (ko) 2012-11-09
MX346393B (es) 2017-03-17
SG181722A1 (en) 2012-07-30
EP2513093B1 (fr) 2014-08-27
US11731981B2 (en) 2023-08-22
IL219421A (en) 2015-07-30
PE20121614A1 (es) 2012-12-21
US20240109909A1 (en) 2024-04-04
EP3091012A1 (fr) 2016-11-09
US9670222B2 (en) 2017-06-06
PT3091012T (pt) 2018-06-27
AU2010332969B2 (en) 2015-02-12
US10196402B2 (en) 2019-02-05
PL2513093T3 (pl) 2015-03-31
CA2782464C (fr) 2016-11-29
MY160471A (en) 2017-03-15
PT2513093E (pt) 2014-10-22
EP2813503A1 (fr) 2014-12-17
BR112012015873B1 (pt) 2021-06-01
TWI473800B (zh) 2015-02-21
AR079636A1 (es) 2012-02-08
EP3091012B1 (fr) 2018-04-11
AU2010332969A1 (en) 2012-05-31
ES2674275T3 (es) 2018-06-28
CL2012001311A1 (es) 2012-10-12
IL219421A0 (en) 2012-06-28
HRP20141143T1 (hr) 2015-01-02
US20220002310A1 (en) 2022-01-06
CN102933579A (zh) 2013-02-13
CN102933579B (zh) 2015-07-15
BR112012015873A2 (pt) 2019-09-24
US8765949B2 (en) 2014-07-01
SI2513093T1 (sl) 2014-11-28
US20190300541A1 (en) 2019-10-03
US20140235661A1 (en) 2014-08-21
CO6650336A2 (es) 2013-04-15
ECSP12012010A (es) 2012-08-31
PL3091012T3 (pl) 2018-08-31
GEP20146124B (en) 2014-07-25
EP2513093A1 (fr) 2012-10-24
AP3170A (en) 2015-03-31
JP5632014B2 (ja) 2014-11-26
NZ599770A (en) 2014-06-27
CA2782464A1 (fr) 2011-06-23
PH12012501215A1 (en) 2015-11-13
JP2013514301A (ja) 2013-04-25
US20170362249A1 (en) 2017-12-21
DK2513093T3 (da) 2014-09-29
EA201200876A1 (ru) 2013-01-30
US20120004252A1 (en) 2012-01-05
CY1115873T1 (el) 2017-01-25
HK1178147A1 (en) 2013-09-06
TW201130816A (en) 2011-09-16
ME01908B (me) 2014-12-20
US12209094B2 (en) 2025-01-28
UY33109A (es) 2011-07-29

Similar Documents

Publication Publication Date Title
MA33818B1 (fr) Nouveaux antagonistes du récepteur ccr2 et leurs utilisations
CL2008001593A1 (es) Compuestos derivados de heterociclos, antagonistas para el ccr2; y uso de los compuestos para tratar afecciones o enfermedades del tracto respiratorio, como enfermedad pulmonar obstructiva cronica y asma.
CY1111169T1 (el) Βενζοϊμιδαζολ-2-υλ πυριμιδινες και πυραζινες ως τροποποιητες του υποδοχεα ισταμινης h4
ECSP11011163A (es) Pirimidin-4-carboxamidas cíclicas en calidad de antagonistas del receptor CCR2 para el tratamiento de inflamación, asma y EPOC
ATE533762T1 (de) Chinolin- oder isochinolinsubstituierte p2x7- antagonisten
DOP2010000165A (es) 4-(4-ciano-2-tioaril) dihidropirimidinonas y su uso como inhibidores de la elastasa neutrofila humana
ATE524450T1 (de) 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren
CL2008003549A1 (es) Compuestos derivados de glucocorticoides; procedimientos de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades a la piel como eczema, afecciones a la nariz, garganta y pulmones como rinitis o asma, enfermedades inflamatorias del intestino, oculares y autoinmunes.
TN2011000171A1 (en) Isonicotinamide orexin receptor antagonists
MY165113A (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
UA107188C2 (uk) Карбоксамідні похідні хіназолінів або хінолінів та фармацевтична композиція на їх основі
BR112015018071A2 (pt) estra-1,3,5(10),16-tetraeno-3-carboxamidas
EA201171172A1 (ru) Применение в терапии производных хиназолиндиона
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
UY33889A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxiquinazolin-6-iloxi]-1,4-diaza-espiro[5 .5]undecan-5-ona, su uso como medicamento y su preparación
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
MX2010009574A (es) 2-aminoquinolinas.
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
SG179203A1 (en) Novel arylated camphenes, processes for their preparation and uses thereof
TR201000733A2 (tr) Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
EA201200855A1 (ru) Модуляторы crth2